Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →What's hot!
View all perspectives
What's Hot
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
BE BOLD: Going Where No PsA Trial Has Gone Before
Dr. Aurelie Najm discusses abstract LB0001 presented at the 2026 EULAR Congress in London
Watch video →
New biomarkers in RA: Who to treat, Who to watch, Who to taper?
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Read more →
Debate: Combination Therapies for Inflammatory Arthritis?
Dr. Jonathan Kay reports on the debate, "Combination of targeted therapies in inflammatory arthritis - is the time now?", from EULAR 2026.
Watch video →
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented in London at the EULAR 2026 Congress.
Watch video →
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 16 hours ago
#EULAR2026 POS0683 Additional analysis of ALLEGORY RCT: in addition to meeting primary endpoint (SRI-4) and 5 key secondary endpoints, Obinutuzumab led to greater DORIS remission and LLDAS vs PBO in nonrenal #SLE. Under FDA review for license extension to non-renal @RheumNow https://t.co/HhZNX3w8v5
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
Does sequential therapy infliximab —> tofacitinib outperform tofa alone in axSpA?
Yes: faster remission at week 4 (84.6% vs 15%)
But: equal at week 24
Prospective study in 46 patients
#POS0201 #EULAR2026 @RheumNow https://t.co/rmtoJQtYc0
Mrinalini Dey DrMiniDey
6 days 16 hours ago
Top tips:
⭐️ Summarise the key facts but always provide the source
⭐️ Learn from mistakes to improve what you have
⭐️ Have high quality source material- scan multiple resources for the best quality info and latest news!
@RheumNow
#EULAR2026
Mrinalini Dey DrMiniDey
6 days 16 hours ago
What makes a good rheum learning platform?
@rheumnow’s Dr Jack Cush gives a masterclass in online learning and medical education, including the background to RheumNow.
#EULAR2026 @EMEUNET https://t.co/2cXpRXPK13
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
What do you think about this cartoon-style format for posters?
A- I love it!
B- It’s Ok but I prefer classic
As for the content: Axia digital therapeutic app improves mobility, BASDAI, sleep an sexual function in 32 patients
#POS0199 #EULAR2026 @rheumnow https://t.co/mV83dMF4vi
Dr. John Cush RheumNow
6 days 16 hours ago
Our expanded #EULAR2026 coverage is made possible by support from Bristol Myers Squibb and UCB. All content is independently chosen and produced by the RheumNow faculty.
Md Yuzaiful Md Yusof Yuz6Yusof
6 days 16 hours ago
#EULAR2026 OP0341 Phase I Obe-Cel Autologous CD19 CAR-T (advantage: 4-1BB-ζ, fast off-rate binding domain to reduce immunotoxicity) showed efficacy and acceptable safety with either 50M or 100M dose in N=13 patients with refractory #SLE. Need longterm data & comparators @RheumNow https://t.co/qxidRi0jit
TheDaoIndex KDAO2011
6 days 16 hours ago
OMRF study: Anti-Ro neg Sjögren’s patients share similar molecular profiling as anti-Ro positive pts: innate immune signaling, immune cell activation, inflammation, autophagy, apoptosis, and metabolic dysregulation pathways #EULAR2026 @RheumNow https://t.co/zJm6EbpyIB
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
Which imaging test has the highest carbon footprint???
Think wisely before prescribing 🩻
#EULAR2026
@RheumNow https://t.co/36Ej8smWRd
Mrinalini Dey DrMiniDey
6 days 16 hours ago
Did you take part in #RheumaVision this year?
@cristianasieiro takes us through the past, present & future of this innovative initiative, which held its final yesterday at #EULAR2026.
You can watch all the videos online- and be sure to participate next year!
@EMEUNET
@RheumNow https://t.co/liWzYYbIxI
Here is my summary of what EULAR 2026 is presenting to us in the field of biomarker-driven personalized care in RA.
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
🩺🌳When good clinical practice meets reducing environmental burden of healthcare:
Rheumatologists can do a lot!
Less is more ⬇️
Thank you @eular_org for planning environmental awareness sessions
Looking forward to #greener congresses
#EULAR2026
@RheumNow https://t.co/5FwARRi92m
Mrinalini Dey DrMiniDey
6 days 16 hours ago
#RheumMadness comes to #EULAR2026!
Dr David Leverenz takes us through the background and process of this firm favourite in rheum education. An excellent example of gamification for medical education more broadly.
@RheumNow https://t.co/lmgkJbTgBm
Nelly ZIADE 🍀 Nellziade
6 days 16 hours ago
Another reason for NOT prescribing ANA (and other tests) as a “screening” test when not indicated:
High carbon footprint!
#EULAR2026
@rheumnow https://t.co/BAuzQuZ0Iv
